LB Pharmaceuticals Inc Common Stock
LBRX
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.4B
$47.10
▼ -0.34%
P/E
-15.86
Mkt Cap
$1.4B
52-Wk Range
$13.36–$50.16
52-Week Range
$13.36 - $50.16
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 172.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary methylated derivative chemistry with improved pharmacological profile
- Focused pipeline targeting high-prevalence neuropsychiatric indications with significant unmet needs
- Novel mechanism of action based on amisulpride modification reducing side effects
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Advancement of LB-102 through clinical trial phases toward regulatory approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+74.3% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying LBRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 11, 2026
Reported EPS of -$1.71 vs -$0.80 consensus (-112.8% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-112.8%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 24, 2026
vs Industry
How LBRX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related